RTP Mobile Logo

Friday-Sunday, February 22-24, 2019, Miami, Florida

The First Annual Miami General Medical Oncology Symposium

Event Details

Dates:
February 22-24, 2019

Location:
Turnberry Isle Miami
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: (305) 932-6200

Meeting Room:
Grand Ballroom A-D (Lobby Level)
Hotel Accommodations:
A special discounted room rate of $329 (plus applicable tax and resort fee) is available to conference attendees at Turnberry Isle Miami. Please see the Location tab for additional details.

 
Note from Moderator
In February 2019 Research To Practice will host the inaugural Miami General Medical Oncology Symposium. This one-of-a-kind offering will span 3 days and feature a stellar multidisciplinary faculty panel and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. To augment the conference interactivity, each clinician will be provided with a specially configured iPad® to use throughout the program to participate in audience polling, view all the presentation slides and anonymously submit questions to the panelists. The conference’s educational design and the topics that will be discussed offer interested clinicians the opportunity to access the in-depth perspectives of some of the top minds in the field regarding significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with myriad forms of cancer.

As you begin to make your plans for 2019, we hope you will join us in sunny South Florida for a learning experience unlike any other.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida

Faculty:

Friday — 6:30 PM – 8:30 PM

Keynote Lecture: Chimeric Antigen Receptor T-Cell Therapy — A New Era in Cancer Immunotherapy

David L Porter, MD
Abramson Cancer Center, University of Pennsylvania Health System
Jodi Fisher Horowitz Professor of Leukemia Care Excellence
Director, Blood and Marrow Transplantation
Philadelphia, Pennsylvania

Keynote Panel

Sattva S Neelapu, MD
Professor and Deputy Chair ad interim
Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Additional faculty to be announced

Saturday — 8:00 AM – 4:30 PM

ER-Positive, HER2-Negative Breast Cancer

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George W Sledge Jr, MD
Professor of Medicine
Chief, Division of Oncology
Department of Medicine
Stanford University School of Medicine
Stanford, California

HER2-Positive and Triple-Negative Breast Cancer

Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas

Additional faculty to be announced

Melanoma

Adil Daud, MD
Professor of Medicine
University of California, San Francisco
San Francisco, California

Evan J Lipson, MD
Assistant Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Chronic Lymphocytic Leukemia

Matthew S Davids, MD, MMSc
Associate Director, Center for Chronic Lymphocytic Leukemia
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Additional faculty to be announced

Hodgkin and Non-Hodgkin Lymphomas

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Craig Moskowitz, MD
Physician in Chief, Cancer Service Line
Sylvester Cancer Center
University of Miami
Miami, Florida

Ovarian Cancer

Robert L Coleman, MD
Professor and Vice Chair, Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Pancreatic Cancer

Andrew Ko, MD
Professor
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD
Associate Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony B El-Khoueiry, MD
Associate Professor of Clinical Medicine
Norris Cancer Center CISO Chair
University of Southern California
Los Angeles, California

Colorectal and Gastric Cancer

Peter C Enzinger, MD
Director, Center for Esophageal and Gastric Cancer
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Charles S Fuchs, MD, MPH
Richard Sackler and Jonathan Sackler
Professor of Medicine (Medical Oncology)
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut

Sunday — 8:00 AM – 12:00 PM

Prostate Cancer

Maha HA Hussain, MBChB
Genevieve E Teuton Professor of Medicine
Professor of Medicine (Hematology and Oncology)
Robert H Lurie Medical Research
Chicago, Illinois

A Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Renal Cell Carcinoma and Bladder Cancer

Elizabeth R Plimack, MD, MS
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

David I Quinn, MBBS, PhD
Medical Director
Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Acute Leukemias

Daniel Pollyea, MD, MS
Clinical Director of Leukemia Services
Assistant Professor of Medicine
Anschutz Medical Campus
University of Colorado
Aurora, Colorado

Richard M Stone, MD
Director, Adult Leukemia Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Targeted Treatment of Lung Cancer

Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Immune Checkpoint Inhibitors in Lung Cancer

Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Joel W Neal, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford University
Palo Alto, California

 

Agenda

Full agenda will be made available later this year. Times and schedule are subject to change.

Preliminary Agenda
  • The meeting will feature a multitumor format focused on the solid and hematologic cancers that make up the majority of general medical oncology practice.
  • In response to the phenomenal surge in new drug approvals, a major emphasis of the meeting will be the safe and appropriate integration of novel agents into current management algorithms.
  • A segment of each tumor-specific module will include a sample board review designed to help clinicians prepare for recertification.
  • Interactive polling and a proprietary live chat function will allow peer-to-peer comparison and commentary throughout the event.
  • The program will include extensive opportunities for audience members to register their opinions and perspectives to help better define the current realities of general medical oncology practice and shape future educational resources.

Friday, February 22nd

6:30 PM – 7:00 PM
Welcome Reception

7:00 PM – 7:30 PM
Keynote Lecture: Chimeric Antigen Receptor T-Cell Therapy — A New Era in Cancer Immunotherapy
David L Porter, MD

7:30 PM – 8:30 PM
Panel Discussion and Moderated Q&A Session
David L Porter, MD
Sattva Neelapu, MD
Additional faculty to be announced

Saturday, February 23rd

8:00 AM – 8:45 AM
ER-Positive, HER2-Negative Breast Cancer
Harold J Burstein, MD, PhD
George W Sledge Jr, MD

8:45 AM – 9:30 AM
HER2-Positive and Triple-Negative Breast Cancer
Joyce O’Shaughnessy, MD
Additional faculty to be announced

9:30 AM Break

9:45 AM – 10:35 AM
Melanoma
Adil Daud, MD
Evan J Lipson, MD

10:35 AM – 11:25 AM
Chronic Lymphocytic Leukemia
Matthew S Davids, MD, MMSc
Additional faculty to be announced

11:25 AM – 12:15 PM
Hodgkin and Non-Hodgkin Lymphomas
John P Leonard, MD
Craig Moskowitz, MD

12:15 PM Lunch

1:05 PM – 1:55 PM
Ovarian Cancer
Robert L Coleman, MD
Ursula A Matulonis, MD

1:55 PM – 2:40 PM
Pancreatic Cancer
Andrew Ko, MD
Philip A Philip, MD, PhD

2:40 PM Break

2:55 PM – 3:40 PM
Hepatocellular Carcinoma
Ghassan Abou-Alfa, MD
Anthony B El-Khoueiry, MD

3:40 PM – 4:35 PM
Colorectal and Gastric Cancer
Peter C Enzinger, MD
Charles S Fuchs, MD, MPH

Sunday, February 24th

8:00 AM – 8:50 AM
Prostate Cancer
Maha HA Hussain, MBChB
A Oliver Sartor, MD

8:50 AM – 9:40 AM
Renal Cell Carcinoma and Bladder Cancer
Elizabeth R Plimack, MD, MS
David I Quinn, MBBS, PhD

9:40 AM – 10:30 AM
Acute Leukemias
Daniel Pollyea, MD, MS
Richard M Stone, MD
10:30 AM Break

10:45 AM – 11:35 AM
Targeted Treatment of Lung Cancer
Geoffrey R Oxnard, MD
Lecia V Sequist, MD, MPH

11:35 AM – 12:15 PM
Immune Checkpoint Inhibitors in Lung Cancer
Matthew Gubens, MD, MS
Joel W Neal, MD, PhD

CE Information

Target Audience:
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic, ovarian and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

Accreditation Statements:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CME Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statement:
This educational activity for 10.5 contact hours is provided by Research To Practice.

This activity is awarded 10.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification:
This program will be submitted for ONCC/ILNA certification.

CME Credit Form:
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form:
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Educational Support:
This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genomic Health Inc and Seattle Genetics. Additional support to be announced.

Research To Practice CME/CNE Planning Committee Members, Staff and Reviewers: Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Location

Turnberry Isle Miami
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: (305) 932-6200

Meeting Room:
Grand Ballroom A-D (Lobby Level)

Room Reservations:
A special discounted room rate of $329 (plus applicable tax and discounted resort fee of $10) is available to conference attendees at the Turnberry Isle Miami hotel. Instructions on how to secure accommodations will be included in your registration confirmation email.

Room reservations must be made by Friday, February 1, 2019. A limited number of rooms are available, and we encourage you to make your reservations early. After Friday, February 1, 2019, the hotel will offer the best rates based on room availability.


Registration

This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Registration Fees:
This event is free of charge for practicing physicians, fellows, nurses and other healthcare providers involved in the treatment of cancer.

For all other individuals, including industry professionals,* a conference registration fee of $850 is available through February 1, 2019 and then $950 after this day. All fees processed will be nonrefundable after January 30, 2019 (5:00 PM Eastern Time). To cancel your registration, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals

I am employed by a for-profit organization, including a financial institution, biotech or pharmaceutical company.

Registration for other/industry professionals »
 
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.